Immunosuppression in an endemically TB infected environment
|
|
|
- Madeline Greer
- 5 years ago
- Views:
Transcription
1 Immunosuppression in an endemically TB infected environment Falk Symposium 151, Sydney Dr Choon Jin Ooi MBBS, FAMS, FRCP (Edin.) Inflammatory Bowel Disease Centre Singapore General Hospital
2
3 Outline Tuberculosis infection in Asia-Pacific IBD - an emerging disease in Asia-Pacific Immunosuppresssion & TB Strategies to diagnose & manage LTBI/active TB Immunosuppression unmasking TB
4 Outline Tuberculosis infection in Asia-Pacific IBD - an emerging disease in Asia-Pacific Immunosuppresssion & TB Strategies to diagnose & manage LTBI/active TB Immunosuppression unmasking TB
5 Tuberculosis - Epidemiology More than 50% of TB occurs in Asia-Pacific Ten out of 22 high TB burden countries are in Asia Pacific - India, China, Indonesia, Bangladesh, Pakistan, Philippines, Vietnam, Thailand, Myanmar & Cambodia
6 Tuberculosis Among those with TB and HIV, 22% live in South East Asia Multi-resistant TB is emerging
7 Tuberculosis in India India has the highest TB cases world-wide ~ 30% WHO estimates one in two adults infected 0.5Mdie each year in India alone
8 Tuberculosis - Management Issues Inappropriate management Multi resistance Co-infection with HIV Insufficient DOTS provision Treatment noncompliance
9 Outline Tuberculosis infection in Asia-Pacific IBD - an emerging disease in Asia-Pacific Immunosuppresssion & TB Strategies to diagnose & manage LTBI/active TB Immunosuppression unmasking TB
10
11 Japan
12 South Korea
13 Prevalence of IBD in Singapore Ulcerative Colitis Tan /100,000 Lee /100,000 Ooi 2005 ~17/100,000 Crohn s Disease Tan /100,000 Lee /100,000 Thia /100,000
14 Per 100,000 Prevalence Trends in Singapore CD UC
15 IBD Prevalence across countries 250 North America: Olmstead MN ' Europe : copenhagen ' Europe : UK '95 Asia : Punjab India '99 Asia : Japan '91 50 Asia : China '00 0 Per 100,000 UC CD Asia : Singapore '00
16 IBD Prevalence across countries 250 North America: Olmstead MN ' Europe : copenhagen ' Europe : UK '95 Asia : Punjab India '99 Asia : Japan '91 50 Asia : China '00 0 Per 100,000 UC CD Asia : Singapore '00
17 Outline Tuberculosis infection in Asia-Pacific IBD - an emerging disease in Asia-Pacific Immunosuppresssion & TB Strategies to diagnose & manage LTBI/active TB Immunosuppression unmasking TB
18 Immunosuppression Steroids Azathioprine/6-mercaptopurine Methotrexate MMF Biologics - anti-tnf antibody
19 Steroids & TB Tuberculosis in immunosuppressed patients. Millar JW, Horne N. Lancet Jun 2;1(8127): patients described Indications for immunosuppressive therapy were varied, but all patients received high doses of corticosteroids with azathioprine in addition in 2 cases and chlorambucil in a third. The diagnosis was delayed in all cases because of suppression of symptoms, so that 4 patients died, 3 directly as a result of tuberculosis
20 Steroids & TB Tuberculosis in immunosuppressed patients. Millar JW, Horne N. Lancet Jun 2;1(8127): A clear policy of investigation and, if indicated, chemoprophylaxis is necessary for all patients with long-term immunosuppressive therapy A high index of suspicion for tuberculosis must be maintained with regular clinical and radiological review
21 Azathioprine/6-mercaptopurine In our centre, where there are 450 UC and 140 CD patients on the registry, at least one have been diagnosed with TB so far Azathioprine dosed at 2.5 mg/kg BW along with prednisolone 5 mg om Presented with cough for 2 weeks Suspected on CXR and confirmed on BAL
22 Mycophenolate Mofetil MMF seem more potent Risk of TB activation appear higher 1: Prokopenko E, Scherbakova E, Vatazin A, Pasov S, Budnikova N, Agafonova S. Does mycophenolate mofetil increase the incidence of infections in renal transplant recipients? Drugs Exp Clin Res. 2005;31(5-6): : Mercadal L, Foltz V, Isnard-Bagnis C, Ourahma S, Deray G. Tuberculosis after conversion from azathioprine to mycophenolate mofetil in a long-term renal transplant recipient. Transplant Proc Dec;37(10): : Skhiri H, Guedri Y, Souani Y, Achour A, Bouraoui S, Frih A, Dhia BN, Elmay M. Primary tuberculosis 1 year after conversion from azathioprine to mycophenolate in recipient kidney transplantation: a case report. Transplant Proc Nov;35(7):
23 Biologics - anti-tnf therapy Tuberculosis associated with infliximab, a tumor necrosis factor alphaneutralizing agent. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD,Siegel JN, Braun MM. N Engl J Med Oct 11;345(15): ,000 patients received infliximab as of May 29, reported cases of tuberculosis after treatment with infliximab, for a median of 12 weeks.
24 Biologics - anti-tnf therapy Tuberculosis associated with infliximab, a tumor necrosis factor alphaneutralizing agent. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD,Siegel JN, Braun MM. N Engl J Med Oct 11;345(15): /70 had extrapulmonary disease (17 had disseminated disease, 11 lymph node disease, 4 peritoneal disease, 2 pleural disease, and 1 each meningeal, enteric, paravertebral, bone, genital, and bladder disease). 64/70 were from countries with a low TB incidence
25 Biologics - anti-tnf therapy Tuberculosis associated with infliximab, a tumor necrosis factor alphaneutralizing agent. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD,Siegel JN, Braun MM. N Engl J Med Oct 11;345(15): Before prescribing the drug, physicians should screen patients for latent tuberculosis infection or disease
26 Anti-TNF and TB Morbidity & Mortality WR, CDC. Aug 6, 2004
27 Anti-TNF and TB Morbidity & Mortality WR, CDC. Aug 6, 2004
28 Anti-TNF and TB TB occurs within 3 cycles of treatment, with a median of 12 weeks Most TB occurred in extra pulmonary sites TB rates in US patients treated was 6 times that of untreated patients Keane J et al N Engl J Med 2001;345: Gardam MA et al. Lancet Infect Dis 2003;3: Keane J et al. N Engl J Med 2002;346:625 6.
29 Outline Tuberculosis infection in Asia-Pacific IBD - an emerging disease in Asia-Pacific Immunosuppresssion & TB Strategies to diagnose & manage LTBI/active TB Immunosuppression unmasking TB
30 Strategies to exclude LTBI/active TB Careful history & physical examination Tuberculin Testing & Adjunctive Tests Chest X-Rays Diagnostic Microbiology & Resistance Testing
31 Careful history & examination History of TB exposure, infection, or disease Demographic factors (e.g., country of origin, age, ethnic or racial group, occupation) that may increase the patient s exposure to TB or to drug-resistant TB Exclude other medical conditions, especially HIV infection
32 Tuberculin Testing Immunologic basis for the tuberculin reaction. Infection with M.tuberculosis produces a delayedtype hypersensitivity reaction
33 Tuberculin Testing Previous BCG vaccination. Tuberculin reactivity can be caused by BCG vaccination Reactions of >20 mm of induration are not likely caused by BCG
34 Tuberculin Testing HIV infection and cutaneous anergy Anergy testing in IBD patients with immunosuppressives Mow WS, Abreu-Martin MT, Papadakis KA, et al. Clin Gastroenterol Hepatol 2004; 2:
35 QuantiFERON -TB Gold (QFT-Gold) On May 2, 2005, QFT-Gold (Cellestis Ltd, Victoria, Australia), received approval from U.S. FDA in diagnosing Mycobacterium tuberculosis infection, including both latent tuberculosis infection (LTBI) and tuberculosis (TB) disease MMWR, CDC. Dec 16,2005
36 QuantiFERON -TB Gold ELISA test detects the release of IFN-g in whole blood from sensitized persons when incubated with synthetic peptides simulating two proteins in M. tuberculosis: early secretory antigenic target--6 (ESAT-6) and culture filtrate protein--10 (CFP- 10) Because these proteins are absent from all Bacille Calmette-Guérin (BCG) vaccine strains, QFT-G is expected to be more specific for M. tuberculosis. MMWR, CDC. Dec 16,2005
37 QuantiFERON -TB Gold Reaches 90% sensitivity for active TB infection May be even better for diagnosis for LTBI
38 Chest X-rays
39 Chest X-rays
40 Diagnostic Microbiology & Resistance Testing Acid-fast-bacilli (AFB) on a sputum smear or other specimen Culture be done on all specimens, regardless of AFB smear results For all patients, the initial M. tuberculosis isolate should be tested for drug resistance
41 MMWR, CDC. Aug 6, 2004
42 MMWR, CDC. Aug 6, 2004
43 Other recommendations Risk of hepatitis: 280/100,000 for 6 months of Isoniazid Preventing TB in patients with Crohn s disease needing infliximab or other anti-tnf therapy. D S Rampton. Gut 2005;54:
44 Isoniazid for LTBI Strategies to treat latent TB infection that are tailored to the at-risk population can effectively and safely lessen the likelihood of active TB in patients treated with TNF antagonists. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, Montero D, Pascual- Gomez E, Mola EM, Carreno L, Figueroa M; BIOBADASER Group. Arthritis Rheum Jun;52(6):
45 Outline Tuberculosis infection in Asia-Pacific IBD - an emerging disease in Asia-Pacific Immunosuppresssion & TB Strategies to diagnose & manage LTBI/active TB Immunosuppression unmasking TB
46 Crohn s disease Ileocaecal valve Terminal ileum Descending colon
47 TB Caecum
48 Is it Crohn s disease? Is it TB?
49 Crohn s disease - Sites Others Stomach / duodenum + another Rectosigmoid +/- another Small bowel Colon TI / cecum +colon Terminal ileum / cecum % of patients Ooi et al, UEGW 2004
50 TB gut - Sites Rectum Colon TI/cecum+SB TI/cecum+colon TI/cecum % of patients Ooi et al, UEGW 2004
51 Histopathology - Patient B Large, fused granulomas
52 Histopathology - Patient B Fibrosis of muscularis propria - resected specimen
53 TB gut - extra GI involvement Extra-abd LN Pulmonary (old ) Pulmonary None % of patients Ooi et al, UEGW 2004
54 Is it Crohn s disease? Is it TB? Very real diagnostic dilemma Immunosuppression may unmask the real diagnoses Close monitoring if using immunosuppression where there is initial doubt in the diagnosis
55 Summary IBD is emerging in Asia- Pacific where TB is endemic Meticulous work-up and high index of suspicion required to diagnose LTBI/active TB High endemicity of TB compounds the diagnostic dilemma in CD diagnosis & the use of immunosuppression
56 Summary - Chemoprophylaxis in Asia Identifying high risk groups Type of immunosuppression - steroids, anti-tnf agents Type of chemoprophylaxis & toxicity profile Future evolution of Quantiferon-GOLD for diagnosis of LTBI
57 Acknowledgement Massachusetts General Hospital Prof. Daniel K. Podolsky Dr Bruce E. Sands Changi General Hospital Prof. Fock Kwong Ming Mt. Elizabeth & Gleneagles Hospital Dr. Cheong Wei Kuen Dr. Teh Lip Bin Dr. Widjaja Luman National University of Singapore A/Prof. Priyanthi Marian Kumarasinghe Raffles Hospital Dr. Jean Ho Singapore General Hospital Prof. Ng Han Seong A/Prof. Chow Wan Cheng Dr. Kelvin Thia Dr. Ling Khoon Lin Colorectal Polyposis Group
PREVENTING TB IN PATIENTS WITH CROHN S DISEASE NEEDING INFLIXIMAB OR OTHER ANTI-TNF THERAPY
Gut Online First, published on August 19, 2005 as 10.1136/gut.2005.076034 PREVENTING TB IN PATIENTS WITH CROHN S DISEASE NEEDING INFLIXIMAB OR OTHER ANTI-TNF THERAPY DS Rampton Centre for Gastroenterology,
Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis
Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Diagnosis of active TB Screening
Latent tuberculosis (TB) infection (LTBI), a
COMMENTARY Time for a change? Updated guidelines using interferon gamma release assays for detection of latent tuberculosis infection in the office setting Marisa Kardos, BS, and Alexa Boer Kimball, MD,
TUBERCULOSIS. Presented By: Public Health Madison & Dane County
TUBERCULOSIS Presented By: Public Health Madison & Dane County What is Tuberculosis? Tuberculosis, or TB, is a disease caused by a bacteria called Mycobacterium tuberculosis. The bacteria can attack any
Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University
Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University Tuberculosis Estimates USA World Infection 15,000,000 2,000,000,000
PREVENTION OF TUBERCULOSIS. Dr Amitesh Aggarwal
PREVENTION OF TUBERCULOSIS Dr Amitesh Aggarwal 25 to 50 % of persons exposed to intimate contact with active PTB - latent infection with TB. Exposure to index case for 12 hours - high risk of infection.
Errors in Dx and Rx of TB
Errors in Dx and Rx of TB David Schlossberg, MD, FACP Professor of Medicine Temple University School of Medicine Medical Director, TB Control Program Philadelphia Department of Public Health TB Still a
Tuberculosis Tools: A Clinical Update
Tuberculosis Tools: A Clinical Update CAPA Conference 2014 JoAnn Deasy, PA-C. MPH, DFAAPA jadeasy@sbcglobal.net Adjunct Faculty Touro PA Program Learning Objectives Outline the pathogenesis of active pulmonary
Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Madhukar Pai, MD, PhD Author and Series Editor Camilla Rodrigues, MD co-author Abstract Most individuals who get exposed
(2) 83.3% b/w TST and T-SPOT, (2) 77.4% b/w TST and T-SPOT. 77.7% b/w TST and QFT-GIT. QFT-GIT, 22.2% in T-SPOT. TSPOT vs. TST (> 5 mm) vs.
Supplementary Table 1. Study characteristics of the included literature Low to moderate TB endemic region Shovman et al. (2009) [21] Minguez et al. (2012) [16], type 35 RA 35 RA 53 Patients with s (RA
Fundamentals of Tuberculosis (TB)
TB in the United States Fundamentals of Tuberculosis (TB) From 1953 to 1984, reported cases decreased by approximately 5.6% each year From 1985 to 1992, reported cases increased by 20% 25,313 cases reported
CHAPTER 3: DEFINITION OF TERMS
CHAPTER 3: DEFINITION OF TERMS NOTE: TB bacteria is used in place of Mycobacterium tuberculosis and Mycobacterium tuberculosis complex in most of the definitions presented here. 3.1 Acid-fast bacteria
Self-Study Modules on Tuberculosis
Self-Study Modules on Tuberculosis Targe te d Te s ting and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control
Guidance for Identifying Risk Factors for Mycobacterium tuberculosis (MTB) During Evaluation of Potential Living Kidney Donors
Summary and Goals On November 13, 2012, the OPTN/UNOS Board of Directors approved a requirement that all potential living kidney donors undergo evaluation for infection with Mycobacterium tuberculosis
Elevated risk of tuberculosis in patients with rheumatoid arthritis in Japan
ARD Online First, published on July 12, 2006 as 10.1136/ard.2005.047274 Concise report Elevated risk of tuberculosis in patients with rheumatoid arthritis in Japan Toru Yamada, Ayako Nakajima, Eisuke Inoue,
TB Prevention Who and How to Screen
TB Prevention Who and How to Screen 4.8.07. IUATLD 1st Asia Pacific Region Conference 2007 Dr Cynthia Chee Dept of Respiratory Medicine / TB Control Unit Tan Tock Seng Hospital, Singapore Cycle of Infection
Technical Bulletin No. 172
CPAL Central Pennsylvania Alliance Laboratory QuantiFERON -TB Gold Plus Assay Contact: J Matthew Groeller, MPA(HCM), MT(ASCP), 717-851-4516 Operations Manager, Clinical Pathology, CPAL Jennifer Thebo,
Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016
Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016 Randy Culpepper, MD, MPH Deputy Heath Officer/Medical Director Frederick County Health Department March 16, 2016 2 No
Diagnosis and Medical Management of Latent TB Infection
Diagnosis and Medical Management of Latent TB Infection Marsha Majors, RN September 7, 2017 TB Contact Investigation 101 September 6 7, 2017 Little Rock, AR EXCELLENCE EXPERTISE INNOVATION Marsha Majors,
Peggy Leslie-Smith, RN
Peggy Leslie-Smith, RN EMPLOYEE HEALTH DIRECTOR - AVERA TRAINING CONTENT 1. South Dakota Regulations 2. Iowa Regulations 3. Minnesota Regulations 4. Interferon Gamma Release Assay (IGRA)Testing 1 SOUTH
TUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of
TUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of Health and Mental Hygiene TODAY S PRESENTATION Epidemiology
What the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Life Cycle of M. tuberculosis
What the Primary Physician Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Microbiology Epidemiology Common disease presentations Diagnosis of active
Targeted Testing and the Diagnosis of. Latent Tuberculosis. Infection and Tuberculosis Disease
Self-Study Study Modules on Tuberculosis Targeted Testing and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease 1 Module 3: Objectives At completion of this module, learners will
10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose
Disclosures Updates in Tuberculosis I have nothing to disclose Chris Keh, MD Assistant Clinical Professor, Division of Infectious Diseases, UCSF TB Controller, TB Prevention and Control Program, Population
Evaluation and Management of the Patient with Latent Tuberculosis Infection (LTBI)
Evaluation and Management of the Patient with Latent Tuberculosis Infection (LTBI) CURTIS FOWLER MPT,PA C ASSISTANT CLINICAL PROFESSOR UNIVERSITY OF THE PACIFIC Learning objectives Recognize the appropriate
ESCMID Online Lecture Library. by author
Tuberculosis prevention in immunodepressed patients M. Carmen Fariñas Álvarez Infectious Diseases.H.U.Marqués de Valdecilla University of Cantabria, Spain DISCLOSURES I have no potential conflicts with
Life Threatening Intra-abdominal Sepsis in Patients on anti-tnfα Therapy.
Gut Online First, published on November 18, 2005 as 10.1136/gut.2005.085449 Life Threatening Intra-abdominal Sepsis in Patients on anti-tnfα Therapy. S Goode 1, G Tierney 2, C Deighton 3 1 Department of
LATENT TUBERCULOSIS. Robert F. Tyree, MD
LATENT TUBERCULOSIS Robert F. Tyree, MD 1 YK TB OFFICERS Ron Bowerman Elizabeth Roll Mien Chyi (Pediatrics) Cindi Mondesir (Pediatrics) The new guys: Philip Johnson Robert Tyree 2009 CDC TB CASE DEFINITION
ABSTRACT. Original Article Respiratory Diseases
J Korean Med Sci. 2018 Nov 19;33(47):e292 eissn 1598-6357 pissn 1011-8934 Original Article Respiratory Diseases Incidence of Active Tuberculosis within One Year after Tumor Necrosis Factor Inhibitor Treatment
What the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Global Impact of TB
What the Primary Physician Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Common disease presentations Diagnosis of active TB Screening
TUBERCULOSIS AND THE TNF-α INHIBITORS. Lloyd Friedman, M.D. Yale University Milford Hospital
TUBERCULOSIS AND THE TNF-α INHIBITORS Lloyd Friedman, M.D. Yale University Milford Hospital Outline TNF-α Anti-TNF-α medications Rates of tuberculosis Lower rates with etanercept Screening for latent tuberculosis
Screening of HIV-Infected Patients with IGRAs for LTBI. Background. Tuberculosis is the most prevalent in the world.
Screening of HIV-Infected Patients with IGRAs for LTBI Kentaro Sakashita, Akira Fujita, Shuji Hatakeyma Stay strong, Japan! Tokyo Metropolitan Tama Medical Center Department of Pulmonary Medicine Background
ANNUAL TUBERCULOSIS REPORT OREGON Oregon Health Authority Public Health Division TB Program November 2012
ANNUAL TUBERCULOSIS REPORT OREGON 211 Oregon Health Authority Public Health Division TB Program November 212 Page 2 Table of Contents Charts Chart 1 TB Incidence in the US and Oregon, 1985-211... page
Tuberculosis Populations at Risk
Tuberculosis Populations at Risk One-third of the world is infected with TB, an average of one new infection per second Two million people died from tuberculosis in 2010, 1 every 20 seconds TB is the leading
Communicable Disease Control Manual Chapter 4: Tuberculosis
Provincial TB Services 655 West 12th Avenue Vancouver, BC V5Z 4R4 www.bccdc.ca Communicable Disease Control Manual Definitions Page 1 2.0 DEFINITIONS Many of the definitions that follow are taken from
TB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012
TB: Management in an era of multiple drug resistance Bob Belknap M.D. Denver Public Health November 2012 Objectives: 1. Explain the steps for diagnosing latent and active TB role of interferon-gamma release
TB, BCG and other things. Chris Conlon Infectious Diseases Oxford
TB, BCG and other things Chris Conlon Infectious Diseases Oxford Epidemiology Latent TB IGRA BCG >50/100000
Interferon Gamma Release Assay Testing for Latent Tuberculosis Infection: Physician Guidelines
Interferon Gamma Release Assay Testing for Latent Tuberculosis Infection: Physician Guidelines Historically, Latent Tuberculosis Infection (LTBI) diagnosis was based on risk assessment, chest x-ray (CXR)
Diagnosis and Treatment of Tuberculosis, 2011
Diagnosis of TB Diagnosis and Treatment of Tuberculosis, 2011 Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Diagnosis of TB, 2011 Diagnosis follows Suspicion When should we Think TB? Who is
TB Intensive Tyler, Texas December 2-4, 2008
TB Intensive Tyler, Texas December 2-4, 2008 Interferon Gamma Releasing Assays: Diagnosing TB in the 21 st Century Peter Barnes, MD December 2, 2008 TOPICS Use of interferon-gamma release assays (IGRAs)
Tuberculosis Update. Topics to be Addressed
Tuberculosis Update Robert M. Jasmer, M.D. University of California, San Francisco TB Control Section, San Francisco Department of Public Health Topics to be Addressed TB in the USA Screening recommendations
Annual Tuberculosis Report Oregon 2007
Annual Tuberculosis Report Oregon 7 Oregon Department of Human Services Public Health Division TB Program April 8 Page 2 Table of Contents Charts Chart 1 TB Incidence in the US and Oregon, 1985-7.. page
TB Intensive San Antonio, Texas November 11 14, 2014
TB Intensive San Antonio, Texas November 11 14, 2014 Interferon Gamma Release Assays Lisa Armitige, MD, PhD November 12, 2014 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of
Latent Tuberculosis Best Practices
Latent Tuberculosis Best Practices Last Updated September 7, 2016 LTBI Demographics in the US o 13million people in the US with LTBI (estimate) o In 2014, approximately 66% of TB cases in the United States
TB Nurse Case Management San Antonio, Texas July 18 20, 2012
TB Nurse Case Management San Antonio, Texas July 18 20, 2012 IGRA s and Their Use in TB Nurse NCM Lisa Armitige, MD, PhD July 18, 2012 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict
Management of Pediatric Tuberculosis in New Jersey
Management of Pediatric Tuberculosis in New Jersey Helen Aguila, MD NJMS Global TB Institute December 15, 2011 This presentation is in part adapted from Pediatric Tuberculosis by Ann Loeffler, MD : Francis
LATENT TUBERCULOSIS SCREENING AND TREATMENT:
LATENT TUBERCULOSIS SCREENING AND TREATMENT: TB or not TB Christopher Kwong, MD and William Rifkin, MD Week 14 Educational Objectives: 1. Understand who should be screened for latent TB infection and why
Evaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014
Evaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014 Interferon Gamma Release Assays: Understanding the Test David Griffith, BA, MD April 11, 2014 David Griffith, BA, MD has the following
Tuberculin skin testing in inflammatory bowel disease patients from an endemic area of Brazil
braz j infect dis. 2014;18(1):60 64 The Brazilian Journal of INFECTIOUS DISEASES www.elsevier.com/locate/bjid Original article Tuberculin skin testing in inflammatory bowel disease patients from an endemic
Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010
Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010 What is Latent TB Infection (LTBI)? Traci Hadley, RN October 5, 2010 LTBI or TB Disease? Presented by : Traci Hadley, RN
Approaches to LTBI Diagnosis
Approaches to LTBI Diagnosis Focus on LTBI October 8 th, 2018 Michelle Haas, M.D. Associate Director Denver Metro Tuberculosis Program Denver Public Health DISCLOSURES I have no disclosures or conflicts
2016 Annual Tuberculosis Report For Fresno County
206 Annual Tuberculosis Report For Fresno County Cases Rate per 00,000 people 206 Tuberculosis Annual Report Fresno County Department of Public Health (FCDPH) Tuberculosis Control Program Tuberculosis
TB Intensive Houston, Texas October 15-17, 2013
TB Intensive Houston, Texas October 15-17, 2013 Interferon Gamma Release Assays (IGRA s) Lisa Armitige, MD, PhD October 16, 2013 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict
Pathogenesis of Rheumatoid Arthritis. Smolen, J. S. et al. (2012) Nat. Rev. Rheumatol. doi: /nrrheum
1 Pathogenesis of Rheumatoid Arthritis 2 Smolen, J. S. et al. (2012) Nat. Rev. Rheumatol. doi:10.1038/nrrheum 2012.23 Biologic therapies used in the treatment of rheumatoid arthritis 3 Etanercept Infliximab
KJLM. Serial Interferon-gamma Release Assays for the Diagnosis of Latent Tuberculosis Infection in Patients Treated with Immunosuppressive Agents
Korean J Lab Med 2011;31:271-278 Original Article Diagnostic Immunology KJLM Serial Interferon-gamma Release Assays for the Diagnosis of Latent Tuberculosis Infection in Patients Treated with Immunosuppressive
Anti-tumor necrosis factor (anti-tnf) agents have
ORIGINAL ARTICLE Screening for Tuberculosis and Hepatitis B Prior to the Initiation of Anti-tumor Necrosis Therapy Byron P. Vaughn, MD,*, Glen A. Doherty, MD,,, Shiva Gautam, PhD,*, Alan C. Moss, MD,,
ACTIVE TUBERCULOSIS IN MACOMB COUNTY, A Review of TB Program Data,
ACTIVE TUBERCULOSIS IN MACOMB COUNTY, 1996-2010 A Review of TB Program Data, 1996-2010 Prepared by: Janice M. Chang, MBBS, MPH Division Director, Health Promotion and Disease Control Macomb County Health
Disclosures. TB and CoMorbidities Challenges and Opportunities. Burden of TB. Outline of the lecture. Target testing for TB Infection TB HIV 3/25/2012
Disclosures TB and CoMorbidities Challenges and Opportunities E. Jane Carter, M.D. Associate Professor of Medicine Alpert School of Medicine, Brown University Providence, Rhode Island No financial disclosures
Tuberculosis and Diabetes Mellitus. Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant
Tuberculosis and Diabetes Mellitus Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant Learning Objectives Understand the impact of uncontrolled diabetes mellitus (DM) on TB infection
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
TB Partial Update Appendix 1 - Scope NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Tuberculosis: interferon gamma tests for the diagnosis of latent tuberculosis (partial
TB Intensive San Antonio, Texas December 1-3, 2010
TB Intensive San Antonio, Texas December 1-3, 2010 TB Pathogenesis and Transmission Lynn Horvath, MD; TCID December 1, 2010 Tuberculosis Pathogenesis Lynn L. Horvath, MD, FACP, FIDSA Associate Professor
Interferon gamma release assays and the NICE 2011 guidelines on the diagnosis of latent tuberculosis
CLINICAL AUDIT Clinical Medicine 2013, Vol 13, No 4: 362 6 Interferon gamma release assays and the NICE 2011 guidelines on the diagnosis of latent tuberculosis Helen R Mujakperuo, Richard D Thompson and
Contact Investigation and Prevention in the USA
Contact Investigation and Prevention in the USA George D. McSherry, MD Division of Infectious Disease Penn State Children s Hospital Pediatric Section TB Center of Excellence Rutgers Global Tuberculosis
Northwestern Polytechnic University
Clinical Tuberculosis Assessment by Health Care Provider Clinicians should review and verify the information in the Tuberculosis (TB) Screening Questionnaire (attached). Persons answering YES to any questions
TB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection?
Those oral antibiotics are just not working! Inpatient Standards of Care & Discharge Planning S/He s in the Hospital: Now What Do I Do? Dana G. Kissner, MD TB Intensive Workshop, Lansing, MI 2012 Objectives:
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Tuberculosis: interferon gamma tests for the diagnosis of latent tuberculosis (partial update) 1.1 Short title Tuberculosis
TB Classification (ATS/CDC)
bits and pieces Lisa Chen, MD UCSF Pulmonary/Critical Care Curry International Tuberculosis Center 10/2017 TB Classification (ATS/CDC) TB0 No tuberculosis exposure, not infected TB1 Tuberculosis exposure,
A Clinician s Perspective: Improving Rheumatology Patient Care Using the T-SPOT.TB Test
A Clinician s Perspective: Improving Rheumatology Patient Care Using the T-SPOT.TB Test Solomon Forouzesh, MD, FACD, FACR Medical Director Arthritis Care & Treatment Center Clinical Associate Professor
The Epidemiology of Tuberculosis in Minnesota,
The Epidemiology of Tuberculosis in Minnesota, 2011 2015 Minnesota Department of Health Tuberculosis Prevention and Control Program (651) 201-5414 Tuberculosis surveillance data for Minnesota are available
Summary of Key Points WHO Position Paper on BCG Vaccine, February 2018
Summary of Key Points WHO Position Paper on BCG Vaccine, February 2018 1 Introduction This position paper replaces the 2004 WHO position paper on Bacille Calmette-Guérin (BCG) vaccine and the 2007 WHO
Making the Diagnosis of Tuberculosis
Making the Diagnosis of Tuberculosis Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Testing for TB Infection Targeted Testing: Key Points Test only if plan for ensuring treatment De-emphasizes
A look at medical factors that increase the risk for TB disease
A look at medical factors that increase the risk for TB disease Mark Lobato, MD New England TB Consultant Division of Tuberculosis Elimination CDC Overview The spectrum of M. tuberculosis infection Immune
2016 OPAM Mid-Year Educational Conference, Sponsored by AOCOPM Sunday, March 13, 2016
Learning Objectives Tuberculosis Case Discussions: Evaluation for Tuberculosis Infection Melissa C. Overman, DO, MPH, CHES, FAOCOPM Describe appropriate technique for TST placement, reading and interpretation
TB in Corrections Phoenix, Arizona
TB in Corrections Phoenix, Arizona March 24, 2011 Treatment of Latent TB Infection Renuka Khurana MD, MPH March 24, 2011 Renuka Khurana, MD, MPH has the following disclosures to make: No conflict of interests
Jennifer Lam MPH candidate 2009 Johns Hopkins Bloomberg School of Public Health. Preceptors: Wendy Cronin, PhD MT(ASCP), Cathy Goldsborough, RN
Jennifer Lam MPH candidate 2009 Johns Hopkins Bloomberg School of Public Health Preceptors: Wendy Cronin, PhD MT(ASCP), Cathy Goldsborough, RN Phase Symposium: May 6, 2009 Background & Rationale Maryland
INDEX CASE INFORMATION
Instructions for Completing the MDH Tuberculosis Contact Investigation Report Form Please provide as much information as possible. Each field represents information that is important to the contact investigation.
Conflict of Interest Disclosures:
Mady Slater, M.D. Stanford University Medical Center Division of Infectious Diseases 04/23/14 WOEMA webinar Conflict of Interest Disclosures: I have no financial relationships with commercial entities
Latent TB Infection (LTBI)
Latent TB Infection (LTBI) Diagnosis & Treatment of Latent TB Infection (LTBI) Amee Patrawalla MD MPH Assistant Professor UMDNJ-New Jersey Medical School Infection with Mycobacterium tuberculosis without
11/1/2017. Disclosures. Update In Tuberculosis, Indiana Outline/Objectives. Pathogenesis of M.tb Global/U.S. TB Burden, 2016
Disclosures Update In Tuberculosis, Indiana 2017 Bradley Allen, MD, PhD, FACP, FIDSA Indiana University School of Medicine Division of Infectious Diseases Roudebush VAMC Indianapolis Medical Consultant,
Clinical features of active tuberculosis that developed during anti-tumor necrosis factor therapy in patients with inflammatory bowel disease
ORIGINAL ARTICLE pissn 1598-9100 eissn 2288-1956 http://dx.doi.org/10.5217/ir.2016.14.2.146 Intest Res 2016;14(2):146-151 Clinical features of active tuberculosis that developed during anti-tumor necrosis
UNC INFLAMMATORY BOWEL DISEASE DRUG PROTOCOL GOLIMUMAB (SIMPONI)
UNC INFLAMMATORY BOWEL DISEASE DRUG PROTOCOL GOLIMUMAB (SIMPONI) TREATMENT PROTOCOL: Golimumab is a human monoclonal antibody that specifically binds to human tumor necrosis factor alpha (TNFα) and neutralizes
LTBI: Who to Test & When to Treat
LTBI: Who to Test & When to Treat TB Intensive May 10 th, 2016 David Horne, MD, MPH Harborview Medical Center University of Washington DISCLOSURES I have no disclosures or conflicts of interest to report
Tuberculosis Education for the Medical Professional
Tuberculosis Education for the Medical Professional North Dakota Diagnosis and Medical Management of Latent TB Infection Dawn Farrell, RN, BSN, PHN Maria Robles, BSN July 10, 2007 Tuberculosis Education
DIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE
DIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE Annie Kizilbash MD, MPH Assistant Professor University of Texas Health Science Center Staff Physician, Texas Center for Infectious Diseases TB Nurse Case
Tuberculosis: A Provider s Guide to
Tuberculosis: A Provider s Guide to Diagnosis and Treatment of Active Tuberculosis (TB) Disease and Screening and Treatment of Latent Tuberculosis Infection (LTBI) Alameda County Health Care Services Agency
Latent Tuberculosis Infection Reporting Instructions for Civil Surgeons Using CalREDIE Provider Portal
Latent Tuberculosis Infection Reporting Instructions for Civil Surgeons Using CalREDIE Provider Portal Civil surgeons are required to report tuberculosis (TB) screening outcomes that result in latent TB
Contracts Carla Chee, MHS May 8, 2012
Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 Contracts Carla Chee, MHS May 8, 2012 Carla Chee, MHS has the following disclosures to make: No conflict of interests No relevant
Diagnosis Latent Tuberculosis. Disclosures. Case
Diagnosis Latent Tuberculosis Neha Shah MD MPH Field Medical Officer Tuberculosis Control Branch California Department of Public Health Centers for Disease Control and Prevention September 2016 1 Disclosures
Didactic Series. Latent TB Infection in HIV Infection
Didactic Series Latent TB Infection in HIV Infection Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director SF, North Coast and East Bay AETC January 8, 2015 ACCREDITATION
Validity of interferon-c-release assays for the diagnosis of latent tuberculosis in haemodialysis patients
ORIGINAL ARTICLE BACTERIOLOGY Validity of interferon-c-release assays for the diagnosis of latent tuberculosis in haemodialysis patients W. K. Chung 1,2, Z. L. Zheng 1, J. Y. Sung 1, S. Kim 1,H.H.Lee 1,
Barbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and Infectious Disease UT Health Northeast
Practical Aspects for Using the Interferon Gamma Release Assay (IGRA) Test Live Webinar July 14, 2017 Barbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and
Clinical Utility of the QuantiFERON TB-2G Test for Elderly Patients With Active Tuberculosis*
CHEST Clinical Utility of the QuantiFERON -2G Test for Elderly Patients With Active Tuberculosis* Yoshihiro Kobashi, MD, PhD; Keiji Mouri, MD; Shinich Yagi, MD; Yasushi Obase, MD, PhD; Naoyuki Miyashita,
Clinical spectrum and standard treatment of tuberculosis
Clinical spectrum and standard treatment of tuberculosis Graham Bothamley Homerton University Hospital, London, UK 2 nd European Advanced Course in Clinical Tuberculosis 1 Plan of talk Why is there a clinical
International Journal of Innovative Research in Medical Science (IJIRMS)
Open Access Journal Research Article DOI: 10.23958/ijirms/vol02-i11/13 Efficacy of IGRA in the Diagnosis of Tuberculosis and its Correlation with Fluorescence Microscopy and Chest X-Ray in a Tertiary Care
TB EPIDEMIOLOGY. Outline. Estimated Global TB Burden, TB epidemiology
TB EPIDEMIOLOGY TB Clinical Intensive Course Curry International Tuberculosis Center September 30, 2015 Varsha Nimbal, MPH Tuberculosis Control Branch California Department of Public Health 1 Outline TB
TB in the Patient with HIV
TB in the Patient with HIV Lisa Y. Armitige, MD, PhD May 11, 2017 TB Intensive May 9 12, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD, has the following disclosures to
A Case of Tuberculous Arthritis Following the Use of Etanercept
CASE REPORT DOI: 10.3904/kjim.2009.24.4.397 A Case of Tuberculous Arthritis Following the Use of Etanercept Seung Won Choi 1, Jong Joon Ahn 1, Young Tae Hwang 1, Sang Hoon Koh 2, and Sung Do Cho 2 Departments
Didactic Series. Latent TB Infection in HIV Infection
Didactic Series Latent TB Infection in HIV Infection Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director, SF and North Coast AETC March 13, 2014 ACCREDITATION STATEMENT:
Latent TB, TB and the Role of the Health Department
Latent TB, TB and the Role of the Health Department Elaine Darnall, RN, BSN, CIC TB Nurse Consultant Illinois Dept of Public Health March 21, 2018 Elaine Darnall has disclosed that there is no actual or